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A B S T R A C T
At the present time, deceased heart-beating donor kidney allografts are usually stored cold. Extended-criteria
donor (ECD) grafts show higher sensitivity to ischemia–reperfusion damage than standard kidneys. The
increasing use of marginal organs in clinical transplantation urgently requires a more effective preservation
system. Pulsatile hypothermic machine perfusion has shown major advantages over static cold storage in
terms of reduced organ injury during preservation and improved early graft function. This preliminary
study aims to compare pulsatile hypothermic machine perfusion and static cold storage of kidney allografts,
outlining differences in the levels of early inﬂammatory cytokines (TNF-a, IL-2 and IL-1b) and soluble
intracellular adhesion molecule (sICAM-1) in perfusion and preservation liquid.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Kidney transplantation is an effective therapy for end-stage renal
disease, but it is limited today by a persistent shortage of suitable
donor organs. This has prompted the increasing use of extended-
criteria donor (ECD) kidneys, even though these ECD organs are more
likely to have early allograft dysfunction or primary non-function
post-transplant sensitivity due to preservation-based ischemia–
reperfusion injury. 1–4 As the necessity to access ECDorgans increases,
a demand for more effective preservation arises. Hypothermic
machine perfusion (HMP) has recently seen a renewed interest in the
ﬁeld of kidney transplantation. 5 Literature data suggest an advantage
for HMP over static cold storage, and amajor multicenter clinical trial
indeed showed beneﬁts of HMP over cold storage. 6
Aim of this preliminary study was to evaluate beneﬁt of HMP
compared to static cold storage (sCS) in terms of reduced expression
of early inﬂammatory cytokines (TNF-a, IL-2, IL-1b) and soluble
intracellular adhesion molecule type 1 (sICAM-1).
2. Materials and methods
Data from 104 heart-beating donor kidneys offered to our center be-
tween January 2011 andDecember 2012were collected prospectively.
Of 104 kidneys offered, 18 (17.3%) were refused [2011: n =5 (27.8%);
2012: n =13 (82.2%)] and 86 [82.7%; 2011: n = 45 (52.3%); 2012:
n =46 (47.7%)] were employed for kidney transplantation.
Donor quality was assessed using the Nyberg Score (NS). 7 The
Nyberg scoring system is based on seven variables evaluated at the
time of organ procurement. Each variable receives a score expressing
the signiﬁcance of the risk factor, with a total score ranging from 0 to
32 points (Table 1). The kidney is then graded according to the total
score: A (0–5 points), B (6–10 points), C (11–15points), D (>16 points).
The present study considered the 24 kidneys with NS grade C or D.
2.1. Group assignment
Of the 24 kidneys with NS class C or D, the ﬁrst 11 were assigned
to group A and stored with the HMP technique; the other 13 were
assigned to group B and stored with sCS techniques.
2.2. Preservation techniques
After procurement, all kidneys were ﬂushed with 1 liter of preserva-
tion solution (Celsior, Genzyme Sanoﬁ, Cambridge, MA, USA).
Group A: Kidneyswere ﬁrst submerged in the preservation solution
(storage liquid) and stored on melting ice for transport to our
hospital. Mean preservation time was 70±25 minutes. Grafts were
then prepared on bench and connected to an RM3® pulsatile
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Table 1
Scoring of risk factors in the Donor Scoring System for Cadaveric Renal Transplantationa
Risk factor Severity Score Score–Gradeb
Total score Grade
Cause of death Trauma, anoxia, other 0 0–5 A
Ischemic or hemorrhagic CVA 6 6–10 B
History of hypertension (years) None 0 11–15 C
1–9 3 16 D
10 6
Donor clearance (Cockcroft–Gault equation) (mL/min) 90 0
80–89 1
70–79 2
60–69 3
50–59 4
<50 6
Donor age (years) <50 0
50–54 1
55–59 2
60–64 3
65–69 4
70 5
History of diabetes Yes 0
No 3
Preservation time (h) <12 0
12–24 1
25–36 2
>36 3
Renal artery plaque None 0
Mild 1
Moderate 2
Severe 3
Total points available 32
a After Nyberg et al., Donor Scoring System for Cadaveric Renal Transplantation, American Journal of Transplantation 2001;1(2):162–70.
b Items in italics indicate the categories examined in the present study.
perfusion machine (Waters Medical Systems, Rochester, MN, USA)
and perfused with IGL-1 preservative solution (Institut George Lopez
Group, Lissieu, France) for 12±4h at 4°C until transplantation. A ﬁxed
systolic perfusion pressure of 20mmHgwasmaintained. After pulsate
perfusion, macroscopic characteristics and renal vascular resistances
were evaluated in order to asssess transplantability. Renal vascular
resistance >0.6was considered highly associatedwith risk for delayed
graft function (DGF). 8
Group B: Kidneys were submerged in the preservation solution
(storage liquid) and stored on melting ice. Mean preservation time
was 10±4h. Grafts were prepared on bench and macroscopically
evaluated just before transplantation.
2.3. Biochemical analysis
After procurement all kidneys were ﬂushed with 1 liter of preserva-
tion solution. Efﬂuent was collected in all cases (Time 0: T0).
Group A: After pulsatile perfusion, liquid efﬂuent was collected and
stored (Time 1: T1).
Group B: After bench preparation, kidneys were ﬂushed with
preservative solution. Efﬂuentwas collected and stored (Time 1: T1).
All collected liquids were stored in multiple aliquots at −80°C.
Prior to analysis samples were defrosted, visually checked and then
immediately transferred to the automated analyzer. Evaluation of
early pro-inﬂammatory cytokines IL-1b, IL-2, TNF-a and sICAM-1
was performed using commercially available, automated immuno-
luminometric assays (Human Quantikine ELISA Kits, R&D Systems,
Minneapolis, MN, USA). The biochemist responsible for performing
these analyses was blinded to the treatment group.
2.4. Recipient characteristics
Between January 2011 and December 2012, 23 transplantations were
performed employing marginal kidneys of NS class C or D (M:F 3:2,
mean age 67±7y). Ten patients received a kidney fromgroupA (43.5%)
and 13 from group B (56.5%). The two groups were well matched in
terms of gender, age, and co-morbidities.
2.5. Transplantation procedure
Brieﬂy, in all cases an inverted J-shaped “hockey stick” incision was
performed, the graft was placed in the retroperitoneal iliac fossa
and vascular anastomoses were performed between kidney vessels
and external iliac vessels at the conﬂuence of external–internal
iliac vessels. Ureteral implantation was performed with Lich–Gregoir
technique with a double-J ureteral stent. Two drainage tubes were
placed: a 24Ch tube near vessel anastomoses and a 19Ch tube near
urinary bladder anastomose.
2.6. Immunosupressive therapy
Immunosuppressive therapywas performed employing two different
protocols conventionally called Protocol 1 and Protocol 2. All
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patients in both groups received an induction treatment consisting
of monoclonal antibodies (basiliximab [Simulect, Novartis, Basel,
Switzerland]) before graft reperfusion and at fourth post-operative
day.
2.6.1. Protocol 1 (P1)
The same maintenance therapy, including tacrolimus (Prograf, Astel-
las Pharma, Tokyo, Japan), mycophenolic acid (Myfortic, Novartis
Pharma, Basel, Switzerland), together with steroids, was given to all
recipients. The dose of tacrolimus was adjusted so as to maintain
blood trough levels of 10–15ng/mL during the ﬁrst month, and
8–12ng/mL thereafter. Mycophenolic acid was given at the highest
tolerated dose (1440mg/day), mainly based on hematologic toxicity
and gastrointestinal side effects. Steroids were tapered to 4mg/day at
45 postoperative days.
2.6.2. Protocol 2 (P1)
The same maintenance therapy, including ciclosporine (Sandimun
Neoral, Novartis Pharma, Basel, Switzerland), everolimus (Certican,
Novartis Pharma, Basel, Switzerland), together with steroids, was
given to all recipients. The dose of ciclosporine was adjusted so as
to maintain blood trough levels of 1000–1400–ng/mL during the ﬁrst
week and then tapered to 350–450ng/mL at 50 postoperative days.
Everolimus was adjusted so as to maintain blood trough levels of
3–8ng/mL. Steroids were tapered to 4mg/day at 45 postoperative
days.
2.7. Follow-up assessment
For the purpose of the present study creatinine was assessed at
discharge and at 12 months postoperative.
2.8. Statistical analysis
Data were collected prospectively in a secure database hosted by our
research center. Data are presented asmean ± standard deviation (SD).
Tests for association in 2×2 tables were performed with Pearson’s
chi square with Yates’ correction or with Student’s t-test for paired
data.
3. Results (Table 2, Fig. 1)
3.1. Kidneys, patients and graft survival
Twenty-four kidneys of NS grade C or Dwere employed for this study.
Of these, 1 kidney (4.3%) was not eligible for transplantation due to
high renal resistance detected with HMP (0.76; mean resistance in
group A was 0.32±0.18).
Twenty-three kidney transplantations were performed and no ma-
jor complicationswere observed in the analyzed period [mortality 0%,
morbidity n =4 (17.4%) urinary tract infections]. Mean hospital stay
was 13±4 days. We did not observe cases of DGF, deﬁned as the
absence of a decrease in serum creatinine levels necessitating dialysis
during ﬁrst week post-transplant. At discharge, mean serum level
of creatinine was 1.80mg/dL (group A, 1.49±0.45mg/dL; group B,
2.07±1.02; p =1×10−1). At 12 months postoperative we registered
2 deaths (8.7%) for cardiovascular causes.Mean serumcreatinine level
1 year post transplantation was 1.5mg/dL (group A, 1.32±0.27mg/dL;
group B, 1.61±0.50, p =1×10−1).
3.2. Biomarker analysis
– TNF-a: At T0,meanTNF-a concentrationwas 0.01pg/mL in all cases.
At T1, mean TNF-a concentration in group A was 0.01±0.01pg/mL
while in group B it was 0.26±0.74pg/mL (p < 1×104).
– IL-2: At T0, mean IL-2 concentration in group A was 33.99±15.50
pg/mL, while in group B it was 23.33±12.12pg/mL. At T1, mean IL-2
concentration in group A was 2.18±1.60pg/mL, while in group B it
was 24.92±12.57pg/mL (p < 1×104).
– IL-1b: At T0, mean IL-1b concentration in group A was 10.00±4.62
pg/mL, while in group B it was 8.33±4.78pg/mL. At T1, mean IL-1b
concentration in group A was 0.09±0.11pg/mL, while in group B it
was 7.01±3.64pg/mL (p < 1×104).
– sICAM-1: At T0, mean sICAM-1 concentration in group A was
5.69±2.16pg/mL, while in group B it was 2.58±1.39pg/mL. At T1,
mean sICAM-1 concentration in group A was 1.28±0.86pg/mL,
while in group B it was 1.76±1.40pg/mL (p =3.34×10−1).
We note here that the kidney considered ineligible for transplantation
due to high vascular resistance detected with HMP shown the highest
levels of TNF-a, IL-2 and IL-1b at T0, while at T1 its TNF-a and IL-1b
levels were below the average value and only IL-2 continued to be
higher than the mean value. The sICAM-1 level was not signiﬁcantly
different from the others in group A.
4. Discussion
sCS is the current standardmethod of preserving grafts for transplan-
tation. Preservation solutions used for sCS typically include colloids,
antioxidants and molecular precursor of ATP that help to reduce
the environmental pressure imposed by hypothermia. HMP is a
dynamic preservation technique in which a continuous circulation
of ﬁltered preservation solution maintains hypothermia and delivers
metabolic substrates to the entire vasculature of the donor graft.
The ﬁrst experimental employment of HMP was performed in the
early 1960s by Folkert Belzer et al. 9 By 1967, the combination
of continuous perfusion with micro-ﬁltered cryoprecipited plasma
and hypothermic storage brought organ preservation to a safer
point. 10 Further research led to the development of new perfusion
solutions and more user-friendly and transportable HMP apparatus
that generates either continuous or pulsatile ﬂow. The principle
of HMP is based on slowing down metabolism, reducing oxygen
requirement and ATP depletion. 11 HMP provides a continuous
supply of nutrients while toxic substrate and free radicals produced
during cold storage can be eliminated. HMP may also decrease
vasospasm and improve additional parameters of organ viability
such as ﬂow and resistance. Pulsatile perfusion maintains the
hemodynamic stimulation on the graft vessels. Notably, pulsatile
ﬂow has been associated with the expression of anti-thrombogenic
genes (e.g. thrombomodulin) 12 and ﬂow-dependent vasoprotective
endothelial genes 13,14 (e.g. Kruppel-like factor 2) responsible for the
inhibition of pro-inﬂammatory responses 12,15,16 and the production
of vasodilators such as nitric oxide. Kozaki et al. showed comparable
outcomewith either pulsatile or continuous perfusion. 17,18 However,
other studies demonstrated improved microcirculation and organ
function when pulsatile perfusion was utilized. 19–21 Wight et al. 22 in
ameta-analysis and systematic review demonstrated a 20% reduction
in delayed graft function when HMP was utilized. Schold et al. 23
analyzed the Scientiﬁc Registry of Transplant Recipients in the United
States and reported that HMP led to an increased utilization of
extended-criteria donation kidneys and a lower incidence of delayed
graft function. Moers et al. 6 demonstrated a signiﬁcant risk reduction
for delayed graft failure in the HMP group (20.8% with HMP vs.
26.5% with cold storage) and a signiﬁcantly improved one-year graft
survival in the HMP group (94% vs. 90%).
Many studies 5 have shown that after 2 hours of ischemic injury a
number of stress-induced cytokines are activated, such as TNF-a, IL-1b
and IL-2. Comparison between the HMP and sCS groups with respect
to expression of early inﬂammatory cytokines has shown a decrease
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Table 2
Comparison between Group A and Group B with respect to early inﬂammatory cytokine and sICAM-1 expression, kidney vascular resistance as detected employing
HMP, and serum creatinine levels at discharge and 1 year post-transplant
Number TNF-a (pg/mL)
Time 0 Time 1
IL-2 (pg/mL)
Time 0 Time 1
IL-1b (pg/mL)
Time 0 Time 1
sICAM-1 (pg/mL)
Time 0 Time 1
HMP
Resistance
Serum creatinine
level (mg/dL)
Discharge 12 months
Group A
1 0.01 0.00 44.26 3.92 12.01 0.26 4.96 1.50 0.19 1.03 1.14
2 0.00 0.01 30.90 3.12 6.56 0.03 9.56 2.04 0.21 1.13 1.27
3 0.00 0.00 22.76 0.69 3.18 0.04 4.01 0.13 0.15 1.01 1.34
4 0.02 0.01 37.68 3.01 12.09 0.12 8.10 1.70 0.36 2.37 1.32
5 0.00 0.00 32.70 2.93 13.41 0.31 6.46 0.00 0.28 1.54 1.44
6 0.01 0.02 1.40 1.20 10.95 0.01 4.78 1.20 0.27 1.67 1.43
7 0.03 0.01 59.18 5.12 18.56 0.07 2.98 0.12 0.76 NAa NAa
8 0.00 0.00 21.05 0.08 8.00 0.01 6.76 2.56 0.56 1.91 1.54
9 0.00 0.00 40.16 1.76 6.01 0.00 4.52 1.73 0.27 1.7 1.68
10 0.01 0.00 49.59 1.97 14.15 0.14 7.55 1.18 0.18 1.06 0.7
11 0.00 0.01 34.16 0.19 5.12 0.00 2.89 1.97 0.25 1.51 1.31
Mean 0.01 0.01 33.99 2.18 10.00 0.09 5.69 1.28 1.49 1.32
SD 0.01 0.01 15.50 1.60 4.62 0.11 2.16 0.86 0.45 0.26
Group B
12 0.03 1.65 34.05 36.83 8.43 9.24 1.76 0.70 2.39 2.12
13 0.00 0.98 21.12 23.69 13.07 7.76 4.80 2.04 1.44 1.69
14 0.01 1.16 34.08 36.82 6.84 8.25 2.89 2.41 1.8 1.25
15 0.05 2.13 20.87 21.14 10.42 10.09 3.58 1.54 2.57 NAb
16 0.02 1.75 8.09 8.56 3.83 5.04 1.93 0.03 1.41 1.73
17 0.00 0.09 16.71 15.74 13.43 3.08 3.23 4.73 1.9 0.93
18 0.01 0.42 30.04 31.23 15.19 1.02 4.09 3.06 4.9 2.29
19 0.00 0.76 14.67 17.59 1.86 8.47 0.06 0.94 1.09 0.88
20 0.01 2.41 39.36 42.07 5.49 7.24 1.51 0.04 1.87 2.07
21 0.03 1.83 22.10 22.18 8.12 9.36 3.49 2.72 1.44 NAb
22 0.02 1.96 0.45 1.50 1.49 2.06 0.42 0.01 1.87 1.9
23 0.00 0.65 20.15 24.39 15.06 14.25 2.93 2.68 1.68 1.57
24 0.00 0.59 41.56 42.28 5.12 5.32 2.89 1.97 2.22 1.9
Mean 0.01 1.26 23.33 24.92 8.33 7.01 2.58 1.76 2.07 1.61
SD 0.02 0.74 12.12 12.57 4.78 3.64 1.39 1.40 1.02 0.50
a Data not available as kidney was not employed.
b Data not available as patient deceased within 12 months from transplantation.
Fig. 1. Comparison between Group A and Group B with respect to early inﬂammatory cytokine and sICAM-1 expression at Time 0 and Time 1 (values are pg/mL).
of TNF-a, IL-2 and IL-1b in the HMP group (p < 1×104). This could
be reasonably due to HMP reducing overall cellular stress response
in the setting of hypoxia and hypothermic shock. In our study we
did not see a signiﬁcant difference between the HMP and sCS groups
in expression of sICAM-1 (p =3.34×10−1), probably because of a more
pronounced arteriosclerosis in small vessels.
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Henry et al. 5 have suggested that removal–dilution of proinﬂam-
matory cytokines during HMP could reduce cells’ autocrine and
paracrine signalling capacity, including a reduction in production of
chemokines and adhesionmolecules such as ICAM-1. Our preliminary
study demonstrated a statistically non-signiﬁcant difference of graft
functional restoration in terms of serum creatinine levels at discharge
and 12 month post-operative between the HMP and sCS groups, but
we note that our preliminary study is limited by low statistical power
due to the small number of grafts examined.
5. Conclusion
Pulsatile perfusion offers the opportunity for an alternative preserva-
tion approach instead of classical static cold storage.HMP signiﬁcantly
reduced proinﬂammatory cytokine expression compared with sCS
controls (Table 1) and consequently tissue antigen expression of
ICAM-1. This could explain howHMPpermits a reduction in leukocyte
activation, and in particular neutrophils, and consequently a decrease
in post-reperfusion activated inﬂammation-mediated acute phase
protein. 5,24,25
It is concluded that ECD kidneys should preferably be preserved
by HMP, minimizing functional alteration and immunogenicity of the
graft. Future studies and trials are in order to enlarge the number of
cases, providing powerful statistical evidence for our suggestion, and
to focus on the pathophysiological mechanism, largely unknown, of
hypothermic mechanical perfusion.
Funding
None.
Disclosure statement
The authors have no conﬂicts of interest to declare.
References
1. Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction
after liver transplantation – a multivariate analysis. Transplantation 1993;55:
807–13.
2. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated
with reduced graft survival: an approach to expanding the pool of kidney donors.
Transplantation 2002;74:1281–6.
3. Rudich SM, Kaplan B, Magee JC, et al. Renal transplantations performed using non-
heart-beating organ donors: going back to the future? Transplantation 2002;74:
1715–20.
4. D’Alessandro AM, Fernandez LA, Chin LT, et al. Donation after cardiac death: the
University of Wisconsin experience. Ann Transplant 2004;9(1):68–71.
5. Henry SD, Nachber E, Tulipan J, et al. Hypothermic machine preservation reduces
molecular markers of ischemia/reperfusion injury in human liver transplantation.
Am J Tranplant 2012;12(9):2477–86.
6. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in
deceased-donor kidney transplantation. N Eng J Med 2009;360:7–19.
7. Nyberg SL, Matas AJ, Rogers M, et al. Donor scoring system for cadaveric kidney
transplantation. Am J Transplant 2001;1(2):162–70.
8. Jochmans I, Moers C, Smits JM, et al. The prognostic value of renal resistance during
hypothermic machine perfusion of deceased donor kidney. Am J Transplant 2011;
11(10):2214–20.
9. Belzer FO, Ashby BS, Gulyassy PF, Powell M. Successful seventeen-hour preser-
vation and transplantation of human-cadaver kidney. N Eng J Med 1968;278(11):
608–10.
10. Belzer FO, AshbyBS,Dunphy JE. 24-hour and72-hour preservation of canine kidney.
Lancet 1967;2(7515):536–8.
11. Xiaodong Y, Ashok J, Xupeng G, et al. Machine perfusion or cold storage in organ
transplantation: indication, mechanisms and future perspectives. Transplant Int
2010;23:561–70.
12. Tullius SG, García-Cardeña G. Organ procurement and perfusion before transplan-
tation. N Eng J Med 2009;360(1):78–80.
13. Boon RA, Horrevoets AJ. Key transcriptional regulators of the vasoprotective effects
of shear stress. Hamostaseologie 2009;29(1):39–40, 41–3.
14. Rao RM, Yang L, Garcia-Cardera G, Luscinskas FW. Endothelial-dependent mecha-
nisms of leukocyte recruitment to the vascular wall. Circ Res 2007;101(3):234–47.
15. Parmer KM, Larman HB, Dai G, et al. Integration of ﬂow-dependent endothelial
phenotypes by Kruppel-like factor 2. J Clin Invest 2006;116(1):49–58.
16. Sebzda E, Zou Z, Lee JS, Wang T, Kahn ML. Transcription factor KLF2 regulates the
migration of naive T cells by restricting chemokine receptor expression patterns.
Nat Immunol 2008;9(3):292–300.
17. Kozaki K, Sakurai E, Tamaki I, et al. Usefulness of continuous hypothermic
perfusion preservation for cadaveric renal grafts in poor condition. Transplant Proc
1995;27(1):757–8.
18. Kozaki K, Sakurai E, Uchiyama M, Matsuno N, Kozaki M, Nagao T. Development
of hypothermic continuous perfusion preservation machine equipped with
nonpulsatile pump and its clinical application. Transplant Proc 2000;32(1):5–9.
19. Divonin AL, Mishchenko BP, Loginova LI, Mikhailova ML. [Changes in the liver
circulation and kidney function during pulsatile and non-pulsatile perfusion].
Anesteziol Reanimatol 1991;(3):36–40.
20. Dutkowski P, Odermatt B, Heinrich T, et al. Hypothermic oscillating liver perfusion
stimulates ATP synthesis prior to transplantation. J Surg Res 1998;80(2):365–72.
21. Fukae K, Tominaga R, Tokunaga S, Kawachi Y, Imaizumi T, Yasui H. The effects of
pulsatile and nonpulsatile systemic perfusion on renal sympathetic nerve activity
in anesthetized dogs. J Thorac Cardiovasc Surg 1996;111(2):478–84.
22. Wight JP, Chilcott JB, Holmes MW, Brewer N. Pulsatile machine perfusion vs. cold
storage of kidney for transplantation: a rapid and systemic review. Clin Transplant
2003;17(4):293–307.
23. Schold JD, Kaplan B, Howard RJ, Reed AI, Foley DP, Meier-Kriesche HU. Are we
frozen in time? Analysis of the utilization and efﬁcacy of pulsatile perfusion renal
transplantation. Am J Transplant 2005;5(7):1681–8.
24. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive
immunity on rejection and tolerance. Transplantation 2008;86(7):889–94.
25. Montalvo-Jave EE, Escalante-Tattersﬁeld T, Ortega-Salgado JA, Pina E, Geller DA.
Factors in the pathophysiology of the liver ischemia–reperfusion injury. J Surg Res
2008;147(1):153–9.
